BENGALURU (Reuters) – Sun Pharmaceutical Industries Ltd, India’s largest drugmaker by revenue, reported a better-than-expected 5.2% rise in third-quarter profit on Tuesday, driven by higher sales of its specialty drugs.
The company, known for its consumer healthcare products such as Revital vitamins and pain relief medicine Volini, said it earned a consolidated net profit of 21.66 billion rupees ($265.23 million) for three months ended Dec.
31, up from 20.59 billion rupees last year.
Analysts, on average, had expected the company to report a profit of 21.26 billion rupees, according to Refinitiv IBES data.
($1 = 81.6660 Indian rupees)
(Reporting by Rama Venkat in Bengaluru; Editing by Janane Venkatraman)
